Usefulness of S100β protein in patients on antithrombotic drugs with mild traumatic brain injury: a prospective cohort study in an emergency department

Xavier Quilcaille, Paul-Georges Reuter, Mélanie Duval, Emma Bajeux, Nicolas Peschanski · 2025

Read Usefulness of S100β protein in patients on antithrombotic drugs with mild traumatic brain injury: a prospective cohort study in an emergency department by Xavier Quilcaille, Paul-Georges Reuter, Mélanie Duval, Emma Bajeux, Nicolas Peschanski (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12849163.txt.

Description

Xavier Quilcaille and co-authors test a blood mark for brain harm after a mild head blow in a 2025 study. The mark is a protein freed when the brain is hurt, and it can spare some patients a head scan, but its worth was murky for those on blood thinners.

The team ran the test at one French emergency ward on two hundred forty-five such patients, most of them old. Scans found brain harm in about one in sixteen. The blood test missed none of them. It came back clear for near a fourth of the group, who could thus have skipped the scan, with a small cash save per head. The authors call the test a safe way to rule out harm in this group.

Catalog record

CREATORXavier Quilcaille, Paul-Georges Reuter, Mélanie Duval, Emma Bajeux, Nicolas Peschanski
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12849163

Browse the full library · About the Tower of Babel